1-20 of 37653 Search Results for

chemotherapy

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res CAN-22-0423.
Published: 21 November 2022
... and characterized to mimic therapeutic resistance in patients. Multi-omic profiling of parental and resistant cells revealed enrichment of genes associated with lineage identity and inflammation in chemotherapy resistant derivatives. Integrated pSTAT3 ChIP-seq and RNA-seq analyses showed pSTAT3 regulates genes...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (22_Supplement): A010.
Published: 15 November 2022
...; Thilo Hackert; Franco Fortunato; Peter Bailey The impact of neoadjuvant chemotherapy on tumor cells is largely unknown with resistance to therapy remaining a significant challenge. We analyzed 171 chemo-naïve and post-chemotherapy resected patient samples (chemoradiotherapy excluded) using RNAseq...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): C020.
Published: 15 November 2022
...Iago De Castro Silva; Anna Bianchi; Nilesh Deshpande; Prateek Sharma; Siddharth Mehra; Peter Hosein; Deukwoo Kwon; Nipun Merchant; Jashodeep Datta Background : Partial/complete pathologic response following neoadjuvant chemotherapy (NAC) in pancreatic cancer (PDAC) patients undergoing...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): A073.
Published: 15 November 2022
... from organoid suspension in 1:1 reduced growth factor Cultrex plating 10uL per well. After 24h, physiologic chemotherapy was applied to match pharmacologic exposure of FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (g/n-pac). Initial response was assessed by normalized change in PCO area at 72h...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): B037.
Published: 15 November 2022
... to undergo surgical resection. There is a desperate need to discover novel ways of treating pancreatic cancer. Understanding of the microbiome may be informative to overcoming chemotherapy resistance, toxicity and improving outcomes and disparities. The aim of this study is to (1) identify changes...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): C029.
Published: 15 November 2022
... the differentiation of myofibroblasts and the deposition of extracellular matrix. However, single agent TGFβ blockade has shown limited efficacy in mouse models of pancreatic cancer. Here we showed that in combination with chemotherapy, using either gemcitabine/n(ab)-paclitaxel or FOLFIRINOX, neutralization of TGFβ...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): PR010.
Published: 15 November 2022
... clinical implications for biomarker development and therapeutic design. In this study, we performed single-cell RNA sequencing on freshly collected human PDAC samples of primary (n=16) or metastatic (n=11) origin, either before (n=20) or after (n=7) chemotherapy. We found a heterogeneous mixture of basal...
Journal Articles
Cancer Res (2022) 82 (21): 4001–4015.
Published: 02 November 2022
...Qianying Guo; Hao Wang; Jiahao Duan; Wenwu Luo; Rongrong Zhao; Yuting Shen; Bijun Wang; Siqi Tao; Yi Sun; Qian Ye; Xiaomin Bi; Hui Yuan; Qiang Wu; Peter E. Lobie; Tao Zhu; Sheng Tan; Xing Huang; Zhengsheng Wu Resistance to chemotherapy remains a major obstacle to the successful treatment of breast...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (20): 3659–3661.
Published: 17 October 2022
...Paolo Tarantino; Sara M. Tolaney Delivering targeted chemotherapy through antibody–drug conjugates (ADC) has emerged as an extremely effective therapeutic strategy for multiple types of cancer. The first agent of this class to be established for treating a solid tumor was trastuzumab emtansine (T...
Images
MLL inhibition enhancing <span class="search-highlight">chemotherapy</span> sensitivity of lung cancer cells.  A–...
Published: 15 November 2022
Figure 4. MLL inhibition enhancing chemotherapy sensitivity of lung cancer cells. A–D, A549 cells were treated with siNC or siMLL-2, and the generated cells were treated with cisplatin or ET. The cell proliferation was measured by the CCK8 assay at day 3 ( A and B ), and the colony-forming activity was determined at day 7 ( C and D ). Right, quantification of colony numbers. n = 3. E, The A549, H1299, H157, H1975, and H1944 cells were cotreated with MI-3 and DDP for 72 hours and cell proliferation was measured by CCK8 assays. n = 3. F, The H157 cells were stably transfected with the empty vector or KrasG12V-overexpressing plasmid via the lentiviral. The transfected cells were cotreated with MI-3 and DDP for 72 hours and cell proliferation was measured by CCK8 assays. n = 3. Data are represented as mean ± SD in A – F . The P values were determined by two-tailed unpaired t tests. Figure 4. MLL inhibition enhancing chemotherapy sensitivity of lung cancer cells. A–D, A549 cells were treated with siNC or siMLL-2, and the generated cells were treated with cisplatin or ET. The cell proliferation was measured by the CCK8 assay at the day 3 (A and B), and the colony-forming activity were determined at the day 7 (C and D), the quantification of colony numbers showed in the right. n = 3. E, The A549, H1299, H157, H1975, and H1944 cells were cotreated treated with MI-3 and DDP for 72 hours and cell proliferation was measured by CCK8 assays. n = 3. F, The H157 cells were stably transfected with the empty vector or KrasG12V-overexpressing plasmid via the lentiviral. The transfected cells were cotreated with MI-3 and DDP for 72 hours and the cell proliferation was measured by CCK8 assays. n = 3. Data are represented as mean ± SD in A–F. The P values were determined by two-tailed unpaired t tests. More
Journal Articles
Cancer Res (2022) 82 (18): 3394–3404.
Published: 16 September 2022
... response. Significance: Integrating MRI data with biologically based mathematical modeling successfully predicts breast cancer response to chemotherapy, suggesting digital twins could facilitate a paradigm shift from simply assessing response to predicting and optimizing therapeutic efficacy...
Includes: Supplementary data
Images
CPSF1 regulates p62-SU–mediated chemoresistance in breast cancer.  A,  CPSF...
Published: 02 November 2022
Figure 6. CPSF1 regulates p62-SU–mediated chemoresistance in breast cancer. A, CPSF1 expression was analyzed in chemotherapy-resistant breast cancer cell lines and parental cell lines (GSE81971 and GSE90564). B, Protein levels of CPSF1 and p62 in MCF7 and MDA-MB-231 cells after the indicated treatment were examined by Western blot analysis. C–F, CPSF1 depletion in both MCF7 and MDA-MB-231 cells significantly abrogated chemoresistance of MCF7 and MDA-MB-231 cells; this effect was largely prevented by forced expression of p62-SU in CPSF1-depleted breast cancer cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student t test in A ; ANOVA test in C–F ). Figure 6. CPSF1 regulates p62-SU–mediated chemoresistance in breast cancer. A, CPSF1 expression was analyzed in chemotherapy-resistant breast cancer cell lines and parental cell lines (GSE81971 and GSE90564). B, Protein levels of CPSF1 and p62 in MCF7 and MDA-MB-231 cells after the indicated treatment were examined by Western blot analysis. C–F, CPSF1 depletion in both MCF7 and MDA-MB-231 cells significantly abrogated chemoresistance of MCF7 and MDA-MB-231 cells; this effect was largely prevented by forced expression of p62-SU in CPSF1-depleted breast cancer cells [*, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student t test in A, ANOVA test in C–F)]. More
Journal Articles
Cancer Res OF1–OF14.
Published: 30 November 2022
... into these questions as it did for dormancy almost a century ago (21, 178). Therapeutic Management of Dormant Metastases: Current Landscape Regardless of the clinical management approach of patients with breast cancer (i.e., surgery, chemotherapy, radiotherapy, or targeted therapy), the fact that relapse happens...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (22_Supplement): B029.
Published: 15 November 2022
... are eligible for surgical resection, while the remaining patients treated with chemotherapy who show poor response. It is critical to define mechanisms that accurately predict patient responses to established or novel therapies. We are developing living biobanks of patient-derived organoids (PDOs) and Cancer...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): B016.
Published: 15 November 2022
...; Dana Pe'er; Nir Hacohen Pancreatic cancer is a lethal disease in part because tumor cells exist in distinct transcriptional phenotypes (e.g. basal and classical states), each with a selective ability to evade current chemotherapy regimens. Two major mechanisms have been suggested for treatment evasion...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): PR023.
Published: 15 November 2022
... to standard-of-care chemotherapy combinations renders its treatment particularly challenging and largely contributes to the devastating prognosis. Gemcitabine, a pyrimidine anti-metabolite, is a cornerstone in PDAC therapy, but resistance remains a major hurdle. Multiple mechanisms of chemoresistance have...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): B048.
Published: 15 November 2022
...Robin Colenbier; Costanza E. Maurici; Ivana Gorbaslieva; Eke van Zwol; Jean-Pierre Timmermans; Elisa Giovannetti; Johannes Bogers In recent years, hyperthermia (HT) is gaining popularity as a therapeutic modality that could potentiate other treatments such as chemotherapy. Although pre-clinical...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): IA017.
Published: 15 November 2022
...Kimberly Perez Pancreatic ductal adenocarcinoma (PDAC) is composed of multiple cell types and a dense extracellular matrix that may support cancer cell proliferation and impede chemotherapy delivery. Cancer-associated fibroblasts (CAF’s) in the tumor microenvironment secrete pro-inflammatory...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): A052.
Published: 15 November 2022
... by response to chemotherapy and clinical outcomes. These include the classical and basal-like states as well as a newly identified neural-like progenitor (NRP) state, which we have previously found to be enriched in primary patient tumors treated with neoadjuvant chemotherapy and radiotherapy. While several...
Journal Articles
Cancer Res (2022) 82 (22_Supplement): B045.
Published: 15 November 2022
...Md Afjalus Siraj; Xinning Shan; Robert Tseng; Luisa Escobar-Hoyos Pancreatic ductal adenocarcinomas (PDACs) are highly lethal, mostly because they quickly develop resistance to current chemotherapies: Gemcitabine (GEM)/paclitaxel or cocktail FOLFIRINOX. Both chemotherapies rely on nucleoside...